PHARMACOTHERAPY OF DISEASES OF MUSCULOSKELETAL SYSTEM IN PATIENTS WITH RISK OF COVID-19-ASSOCIATED THROMBOINFLAMMATION

Rekalov D.H.¹, Golovach I.Yu.², Kostenko V.O. ³, Shevchenko M.V.¹, Kulynych R.L.¹

• ¹Zaporizhzhya State Medical University
• ²Feofania Clinical Hospital of the State Directorate for Affairs
• ³Poltava State Medical University

Summary. This article highlights the capability of chondroitin sulfates (CS), known for improving the structure and function of cartilage and bone tissue, to reduce the activation of NF-kappa B, pro-inflammatory hypercytokinemia, and C-reactive protein levels, as well as to produce a positive impact on hemocoagulation. The article provides evidence for effectiveness of standardized bioactive extract of small marine fish (Alflutop) as the drug of choice in the pharmacotherapy of musculoskeletal diseases in patients at risk of COVID-19-associated thromboinflammation. There has been emphasized its ability to correct thromboinflammation by suppressing NF-kappa B-mediated cytokine storm. Alflutop has been also proven to deserve more attention from clinicians for its positive effect on the parameters of hemocoagulation and its low immunogenicity. The pharmacotherapeutic value of Alflutop components, and, in particular, the CS physical and cochemical properties, the presence of certain amino acids (L-arginine) and minerals (zinc compounds) when used in a COVID-19 pandemic, have been discussed.